May 05, 2021
Neurotech International (ASX: NTI) has commenced a Phase I/II open label clinical study in 20 children aged between 5-17 years with ASD.
Get expert stock analysis direct in your inbox
Join OurMailing List
Discover Small CapBiotech Stocks
Join thousands of other Investors following our stock commentary for Free